A cure for the high cost of hepatitis C virus treatment.
作者信息
Etzion Ohad, Ghany Marc G
出版信息
Ann Intern Med. 2015 May 5;162(9):660-1. doi: 10.7326/M15-0674.
Abstract
摘要
相似文献
1
A cure for the high cost of hepatitis C virus treatment.丙型肝炎病毒治疗高昂费用的解决办法。
Ann Intern Med. 2015 May 5;162(9):660-1. doi: 10.7326/M15-0674.
2
[Is more expensive always better?].[价格越高就越好吗？]
Ned Tijdschr Geneeskd. 2014;159:A8556.
3
Special report: cost-effectiveness studies of new hepatitis C treatments.特别报道：新型丙型肝炎治疗方法的成本效益研究
Technol Eval Cent Assess Program Exec Summ. 2015 Jan;29(10):1-3.
4
Sovaldi ushers in wave of costly hepatitis C drugs.索华迪引领了一波昂贵的丙型肝炎药物浪潮。
Manag Care. 2014 Jan;23(1):51.
5
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.州医疗补助计划下新型丙型肝炎病毒治疗的获取受限。
Ann Intern Med. 2015 Aug 4;163(3):226-8. doi: 10.7326/M15-0320.
6
Early Patterns of Sofosbuvir Utilization by State Medicaid Programs.各州医疗补助计划中索磷布韦的早期使用模式。
N Engl J Med. 2015 Sep 24;373(13):1279-81. doi: 10.1056/NEJMc1506108.
7
New expensive treatments for hepatitis C infection.丙型肝炎感染的新型昂贵治疗方法。
JAMA. 2014 Aug 13;312(6):593-4. doi: 10.1001/jama.2014.8897.
8
[Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].[自然疗法咨询。很快所有患者都将可治愈。丙型肝炎治疗取得决定性突破]
MMW Fortschr Med. 2014 Feb 20;156(3):26-7.
9
Cost-effectiveness analysis of new drugs for chronic hepatitis C: the importance of updating utility values.慢性丙型肝炎新药的成本效益分析：更新效用值的重要性
Hepatology. 2015 Mar;61(3):1096-7. doi: 10.1002/hep.27316. Epub 2015 Jan 20.
10
Commentary on "no to greed".对《拒绝贪婪》的评论
South Med J. 2015 Jan;108(1):65-6. doi: 10.14423/SMJ.0000000000000228.
引用本文的文献
1
Marmosets as models of infectious diseases.狨猴作为传染病模型。
Front Cell Infect Microbiol. 2024 Feb 23;14:1340017. doi: 10.3389/fcimb.2024.1340017. eCollection 2024.
2
Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.针对慢性丙型肝炎感染患者减少直接抗病毒药物疗程的反应引导治疗：一项试点研究。
Sci Rep. 2020 Oct 20;10(1):17820. doi: 10.1038/s41598-020-74568-x.
3
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.限制医疗补助患者获得丙型肝炎治疗的政策对经济和公共卫生的影响
Value Health. 2016 Jun;19(4):326-34. doi: 10.1016/j.jval.2016.01.010. Epub 2016 Mar 24.
4
Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship.药品定价标准：价格-销量关系建模的初步经验
Sci Pharm. 2015 Aug 27;84(1):73-9. doi: 10.3797/scipharm.1506-03. Print 2016 Jan-Mar.
5
Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation.基于索磷布韦的治疗方案对意大利北部HIV/HCV合并感染患者的预算影响分析：一项多中心区域模拟研究
Clinicoecon Outcomes Res. 2015 Dec 31;8:15-21. doi: 10.2147/CEOR.S93641. eCollection 2016.
本文引用的文献
1
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.基于索磷布韦的治疗方案用于丙型肝炎病毒2型或3型感染的成本效益
Ann Intern Med. 2015 May 5;162(9):619-29. doi: 10.7326/M14-1313.
2
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.新型丙型肝炎病毒治疗方案的成本效益分析。
Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.
3
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.索磷布韦和来迪帕司韦治疗丙型肝炎病毒在美国的成本效益和预算影响
Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: 10.7326/M14-1336.
4
Therapy of hepatitis C--back to the future.丙型肝炎的治疗——回归未来。
N Engl J Med. 2014 May 22;370(21):2043-7. doi: 10.1056/NEJMe1403619. Epub 2014 May 4.
5
Sofosbuvir (Sovaldi) for chronic hepatitis C.索磷布韦（索华迪）用于治疗慢性丙型肝炎。
Med Lett Drugs Ther. 2014 Jan 20;56(1434):5-6.
6
Hepatitis C in the United States.美国的丙型肝炎
N Engl J Med. 2013 May 16;368(20):1859-61. doi: 10.1056/NEJMp1302973.
7
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.慢性丙型肝炎合并晚期肝纤维化患者持续病毒学应答与全因死亡率的关系。
JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.
8
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.1990年和2010年20个年龄组中235种死因的全球和区域死亡率：全球疾病负担研究2010的系统分析
Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.
Zotero 插件